IGHE and Failure to thrive: Our study provides recent insights on the progression of the CMPA symptoms three to five weeks after a first prescription of the w-eHF Althéra®, according to the evolution of CoMiSS® components as well as other symptoms, such as rectal bleeding, failure to thrive and immediate IgE-like type reaction.